



## Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2023

**SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2023 / [Jaguar Health, Inc.](https://www.jaguarhealth.com)** (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective November 7, 2023, the Company granted 7,500 restricted stock units (RSUs) to one new employee.

These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire.

The RSUs for this new employee were granted as an inducement material to this new employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to this new employee's continued service with Jaguar through the applicable vesting dates.

### About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the [OnTarget](#) study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's [Entheogen Therapeutics Initiative](#) (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit <https://jaguar.health>

Napo Pharmaceuticals, visit [www.napopharma.com](http://www.napopharma.com)

Napo Therapeutics, visit [napotherapeutics.com](http://napotherapeutics.com)

Magdalena Biosciences, visit [magdalenabiosciences.com](http://magdalenabiosciences.com)

Visit Jaguar on LinkedIn: <https://www.linkedin.com/company/jaguar-health/>

Visit Jaguar on X: [https://twitter.com/Jaguar\\_Health](https://twitter.com/Jaguar_Health)

Visit Jaguar on Instagram: <https://www.instagram.com/jaguarhealthcommunity/>

### Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

### Contact:

[hello@jaguar.health](mailto:hello@jaguar.health)

Jaguar-JAGX

**SOURCE:** Jaguar Health, Inc.

[accesswire.com](https://www.accesswire.com)

<https://www.accesswire.com/801313/jaguar-health-announces-new-employee-inducement-grant-under-nasdaq-listing-rule-5635c4>